NASDAQ$ENGN
enGene Therapeutics Inc · Q2 2026 earnings
Q2 2026 earnings · · Investor relations
Briefing
enGene Therapeutics Inc reported a net loss of $30.2 million for the second quarter of 2026.
The clinical-stage biotech company focused on genetic medicines for bladder cancer incurred a net loss of $30.2 million in Q2 2026, driven by R&D and G&A expenses totaling $32.0 million. Cash, cash equivalents and marketable securities stood at $285.2 million at quarter end, supporting ongoing pivotal trial activities for detalimogene. The company remains pre-revenue with no product sales.
- Net loss of $30.2 million for the three months ended April 30, 2026, compared to $25.8 million in the prior year period.
- R&D expenses rose to $22.2 million, reflecting increased clinical operations and personnel costs for the LEGEND trial.
- Cash and marketable securities totaled $285.2 million, providing runway for at least the next 12 months.
- Company plans to initiate BLA submission for detalimogene in the second half of 2026 following FDA engagement.
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
Company expects to initiate BLA submission in second half of 2026 and is implementing workforce reduction to preserve cash.
Tailwinds
- Strong cash position of $285.2 million supports operations
- Pivotal cohort enrollment completed for LEGEND trial
Headwinds
- Ongoing net losses and pre-revenue status
- Workforce reduction of ~50% announced post-quarter
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro